Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Aequus Pharmaceuticals Yönetim

Yönetim kriter kontrolleri 3/4

Aequus Pharmaceuticals' CEO'su Doug Janzen, Jan2013 tarihinde atandı, in görev süresi 11.75 yıldır. şirketin hisselerinin 9.46% doğrudan sahiptir ve bu hisselerin değeri CA$ 156.92K dir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 8.3 yıl ve 5.9 yıldır.

Anahtar bilgiler

Doug Janzen

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	11.8yrs
CEO sahipliği	9.5%
Yönetim ortalama görev süresi	8.3yrs
Yönetim Kurulu ortalama görev süresi	5.9yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Doug Janzen'un ücretlendirmesi Aequus Pharmaceuticals'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	-CA$3m
Mar 31 2024	n/a	n/a	-CA$3m
Dec 31 2023	n/a	n/a	-CA$3m
Sep 30 2023	n/a	n/a	-CA$3m
Jun 30 2023	n/a	n/a	-CA$3m
Mar 31 2023	n/a	n/a	-CA$3m
Dec 31 2022	CA$206k	CA$206k	-CA$3m
Sep 30 2022	n/a	n/a	-CA$3m
Jun 30 2022	n/a	n/a	-CA$2m
Mar 31 2022	n/a	n/a	-CA$2m
Dec 31 2021	CA$225k	CA$225k	-CA$2m
Sep 30 2021	n/a	n/a	-CA$2m
Jun 30 2021	n/a	n/a	-CA$2m
Mar 31 2021	n/a	n/a	-CA$1m
Dec 31 2020	CA$212k	CA$212k	-CA$1m
Sep 30 2020	n/a	n/a	-CA$2m
Jun 30 2020	n/a	n/a	-CA$2m
Mar 31 2020	n/a	n/a	-CA$3m
Dec 31 2019	CA$191k	CA$191k	-CA$3m
Sep 30 2019	n/a	n/a	-CA$3m
Jun 30 2019	n/a	n/a	-CA$3m
Mar 31 2019	n/a	n/a	-CA$3m
Dec 31 2018	CA$180k	CA$180k	-CA$3m
Sep 30 2018	n/a	n/a	-CA$3m
Jun 30 2018	n/a	n/a	-CA$3m
Mar 31 2018	n/a	n/a	-CA$4m
Dec 31 2017	CA$258k	CA$210k	-CA$4m

Tazminat ve Piyasa: Doug şirketinin toplam tazminatının Canadian pazarındaki benzer büyüklükteki şirketlerle karşılaştırıldığında makul olup olmadığını tespit etmek için yeterli veri yok.

Tazminat ve Kazançlar: Doug 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Doug Janzen (55 yo)

11.8yrs

Görev süresi

Mr. Douglas Glen Janzen, also known as Doug, is Director of Elevate Farms Inc. from September 2022. Mr. Janzen has experience in banking investments and managing growth companies with a particular focus on...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Douglas Janzen	Chairman	11.8yrs	Veri yok	9.46% CA$ 125.5k
Ann Fehr	CFO & Corporate Secretary	8.3yrs	CA$112.39k	0.28% CA$ 3.7k
Grant Larsen	Chief Commercial Officer	4.2yrs	CA$274.82k	Veri yok

8.3yrs

Ortalama Görev Süresi

Deneyimli Yönetim: AQS 'un yönetim ekibi deneyimli ve deneyimlidir ( 8.3 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Douglas Janzen	Chairman	11.8yrs	Veri yok	9.46% CA$ 125.5k
Marc Lustig	Independent Director	3.7yrs	CA$3.72k	5.21% CA$ 69.2k
Christopher Clark	Director	9.8yrs	CA$3.72k	Veri yok
Iqbal Ahmed	Chairman of Strategic Advisory Board	5.9yrs	Veri yok	Veri yok
Anne Stevens	Director	9.8yrs	CA$3.72k	Veri yok
Rosa Braga-Mele	Member of Strategic Advisory Board	5.9yrs	Veri yok	Veri yok
Vikram Lekhi	Member of Strategic Advisory Board	5.9yrs	Veri yok	Veri yok
Ken Patterson	Member of Strategic Advisory Board	5.9yrs	Veri yok	Veri yok

5.9yrs

Ortalama Görev Süresi

51yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: AQS 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 5.9 yıldır).

Aequus Pharmaceuticals Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Aequus Pharmaceuticals Inc., Annual General Meeting, Jul 25, 2023

Less than half of directors are independent

Less than half of directors are independent

Aequus Pharmaceuticals Inc., Annual General Meeting, Jun 23, 2022

Aequus Pharmaceuticals Inc. Announces Resignation of Jason Flowerday from the Board of Directors

High number of new directors

Recent updates

Second quarter 2024 earnings released: CA$0.005 loss per share (vs CA$0.005 loss in 2Q 2023)

Full year 2023 earnings released: CA$0.022 loss per share (vs CA$0.024 loss in FY 2022)

Third quarter 2023 earnings released: CA$0.006 loss per share (vs CA$0.004 loss in 3Q 2022)

Second quarter 2023 earnings released: CA$0.005 loss per share (vs CA$0.006 loss in 2Q 2022)

Aequus Pharmaceuticals Inc. Announces Launch of Zimed PF in Canada

Aequus Pharmaceuticals Inc. Announces Pause in Sales of Evolve Intensive Eyedrop and Intensive Gel Products in Canada

First quarter 2023 earnings released: CA$0.006 loss per share (vs CA$0.007 loss in 1Q 2022)

Aequus Pharmaceuticals Inc., Annual General Meeting, Jul 25, 2023

Aequus Announces Health Canada Notice of Compliance (NOC) for Zimed® Preservative Free (Bimatoprost 0.03%)

Third quarter 2022 earnings released: CA$0.004 loss per share (vs CA$0.003 loss in 3Q 2021)

Aequus Pharmaceuticals Inc. Expects Health Canada Approval for Zimed® PF (Preservative Free)

Less than half of directors are independent

Second quarter 2022 earnings released: CA$0.006 loss per share (vs CA$0.004 loss in 2Q 2021)

Less than half of directors are independent

Aequus Pharmaceuticals Inc., Annual General Meeting, Jun 23, 2022

Aequus Pharmaceuticals Inc. Announces Resignation of Jason Flowerday from the Board of Directors

Health Check: How Prudently Does Aequus Pharmaceuticals (CVE:AQS) Use Debt?

Aequus Pharmaceuticals Inc. Announces Canadian Filing of NDS for Preservative-Free Glaucoma Medication

High number of new directors

Is Aequus Pharmaceuticals (CVE:AQS) Using Debt Sensibly?

Third quarter 2021 earnings released: CA$0.003 loss per share (vs CA$0.003 loss in 3Q 2020)

Chairman & CEO recently bought CA$73k worth of stock

Director Marc Lustig has joined 5th company board

Director Marc Lustig has joined 5th company board

Director Marc Lustig has joined 5th company board

Director Marc Lustig has joined 5th company board

Second quarter 2021 earnings released: CA$0.004 loss per share (vs CA$0.003 loss in 2Q 2020)

First quarter 2021 earnings released: CA$0.005 loss per share (vs CA$0.005 loss in 1Q 2020)

Chairman recently bought CA$58k worth of stock

Full year 2020 earnings released: CA$0.011 loss per share (vs CA$0.039 loss in FY 2019)

Chairman exercised options to buy CA$328k worth of stock.

Aequus Pharmaceuticals Inc. Launches Evolve Eyedrops to Eye Care Professionals in Canada

New 90-day high: CA$0.28

Aequus Pharmaceuticals Inc. announced that it has received CAD 1 million in funding

Aequus Pharmaceuticals Inc. Appoints Marc Lustig as a Director

Aequus Pharmaceuticals Inc. announced that it expects to receive CAD 1 million in funding

New 90-day high: CA$0.23

Is Aequus Pharmaceuticals (CVE:AQS) Using Too Much Debt?

Third quarter 2020 earnings released: CA$0.003 loss per share

Aequus Pharmaceuticals Inc. Announces Resignation of Anne Stevens as Chief Operating Officer

Aequus Pharmaceuticals Inc. Receives Approval for New ‘Evolve - Intensive Gel’ Lubricating Eye Drops in Canada

Aequus Pharmaceuticals Inc. Extends Commercial Agreement for Specialty Product Tacrolimus IR in Canada with Sandoz Canada Inc

Aequus Announces Expansion of Medicom Partnership and Filing with Health Canada for Additional Evolve Dry Eye Product

First half earnings released

Aequus Pharmaceuticals Inc. has completed a Composite Units Offering in the amount of CAD 2.5 million.

Aequus Pharmaceuticals Inc.(TSXV:AQS) dropped from S&P/TSX Venture Composite Index

CEO Tazminat Analizi

CEO

Görev süresi

Liderlik Ekibi

Ortalama Görev Süresi

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş